A disease with no licensed vaccine or treatment now has two candidates in human trials
Against a virus that kills between four and seven in ten of those it infects, and for which no licensed treatment exists, humanity has long stood without a shield. This April, sixty volunteers in Belgium will receive the first human doses of a Nipah vaccine developed at the University of Tokyo — a quiet but consequential threshold in the long effort to outpace a pathogen that moves between bats, animals, and people with lethal unpredictability. The trial arrives as fresh cases surface in India and a parallel Oxford effort advances in Bangladesh, suggesting that the scientific world is, at last, moving with the seriousness this disease demands.
- Nipah kills up to three-quarters of those it infects, yet no vaccine or targeted treatment has ever been licensed — leaving exposed populations with no medical recourse when outbreaks ignite.
- India's confirmation of two Nipah cases in West Bengal in January 2026 is a live reminder that the virus is not a distant hypothetical but a recurring and present danger in densely populated regions.
- The University of Tokyo's candidate — a modified measles virus engineered to carry Nipah's genetic signature — has cleared animal trials and is now poised to enter 60 human subjects in Belgium this April, the first such trial in history.
- Oxford University is simultaneously running Phase 2 trials with 300 participants in Bangladesh, and the WHO has designated Nipah a priority disease, signaling coordinated global urgency rather than isolated scientific effort.
- Phase 1 is a narrow gate: its sole purpose is to confirm the vaccine does not harm people — but clearing it would open the path toward the larger trials that could, for the first time, offer real protection to at-risk communities.
Japanese researchers are preparing to cross a historic threshold this April, when 60 volunteers in Belgium will receive the first human doses of a Nipah virus vaccine — a candidate developed at the University of Tokyo that has already demonstrated safety and efficacy in animal studies. The timing is pointed: India confirmed two Nipah cases in West Bengal in January, a reminder that the virus remains an active threat in South Asia.
The vaccine works by embedding Nipah genetic material inside a modified measles virus — a platform with a long safety record — which prompts the immune system to learn the shape of Nipah's proteins and prepare a defense before any real infection arrives. It is an elegant strategy against a disease that currently has no licensed vaccine or specific treatment, and that kills between 40 and 75 percent of those it infects, sometimes through severe respiratory failure, sometimes through fatal brain inflammation.
Nipah is a zoonotic disease, carried primarily by bats and capable of spreading to humans directly, through contaminated food, via pigs, or through close contact in healthcare settings. Its unpredictable presentation and the absence of any targeted therapy have placed it on the WHO's Research and Development Blueprint as a global priority.
The Tokyo team is not working in isolation. Oxford University launched Phase 2 trials of its own Nipah candidate in Bangladesh in December, enrolling around 300 people — a parallel effort that reflects the shared urgency felt across the scientific community. Two candidates, two continents, two trial phases running simultaneously.
For now, everything narrows to Belgium and those 60 participants. Phase 1 exists to answer one question: is this safe in humans? If the answer is yes, the path opens toward larger trials and, eventually, toward a vaccine that could protect the communities where Nipah has long circulated without opposition.
Japanese researchers are moving a potential Nipah vaccine into human testing this April, marking the first time a candidate against this virus will be tested in people. The vaccine, developed at the University of Tokyo, will begin Phase 1 clinical trials in Belgium with 60 human subjects—a critical step after the team confirmed its safety and effectiveness in animal studies using hamsters. The timing arrives as India reported two confirmed cases of Nipah virus in West Bengal in January, underscoring the disease's persistent threat.
The vaccine works by inserting genetic material from the Nipah virus into a modified measles virus, a platform already used safely in measles vaccines worldwide. When introduced into the human body, this engineered virus prompts the immune system to produce proteins that resemble those of Nipah itself, essentially training the body's defenses to recognize and fight the real virus before infection takes hold. No licensed vaccine or specific treatment for Nipah currently exists, making this development significant for a disease with a fatality rate between 40 and 75 percent depending on how quickly it is detected and how well patients are treated.
Nipah is a zoonotic disease, meaning it jumps from animals to humans. Bats are the primary reservoir, transmitting the virus either directly or through contaminated food. The virus can also spread from pigs to people, and in healthcare settings, from person to person through close and prolonged contact. Once in humans, infection can range from asymptomatic to severe respiratory disease and fatal brain inflammation. The unpredictability of its presentation and the absence of targeted treatments have made it a public health concern, particularly in South and Southeast Asia where outbreaks have occurred.
The University of Tokyo effort is not alone. Oxford University began Phase 2 trials of its own Nipah vaccine candidate in Bangladesh in December, enrolling around 300 people aged 18 to 55. This parallel development reflects the urgency: the World Health Organization has designated Nipah as a priority disease under its Research and Development Blueprint, signaling global recognition that a vaccine is needed. The two trials operating simultaneously in different regions and at different phases suggest the scientific community is moving with deliberate speed to establish whether vaccination can protect against a virus that has no other defense.
The April start date in Belgium represents a threshold moment. Phase 1 trials are designed primarily to confirm safety in humans—to ensure that what worked in hamsters does not produce unexpected harm in people. Success would clear the path for larger Phase 2 and Phase 3 trials to test whether the vaccine actually prevents infection. If the Japanese and Oxford candidates both prove effective, the world would have options for protecting populations in regions where Nipah circulates. For now, the focus is narrow and methodical: 60 people in Belgium will receive the vaccine and be monitored closely. Everything that follows depends on what happens next.
Citações Notáveis
When the vaccine is introduced in humans, antigen proteins similar to those of the Nipah virus are produced, strengthening the body's defenses and helping prevent symptom onset— University of Tokyo research team
A Conversa do Hearth Outra perspectiva sobre a história
Why does a vaccine for Nipah matter now, when cases seem relatively rare?
Because Nipah doesn't stay rare. It emerges in clusters—West Bengal just had two cases in January. Without a vaccine, every outbreak is a scramble. A 40 to 75 percent fatality rate means you're not dealing with something you can treat your way out of. You need prevention.
How does inserting Nipah's genetic code into measles actually work?
You're essentially using measles as a Trojan horse. The immune system knows how to respond to measles—we've been vaccinating against it for decades. So when you slip Nipah's genetic instructions inside, the body learns to recognize Nipah without ever facing the real virus. It's training without the danger.
Why Belgium for the first human trial, not Japan?
That's a regulatory question I can't fully answer from what we know. But Belgium is in Europe, which has established infrastructure for clinical trials and regulatory oversight. It may simply be where the partnership and approvals aligned.
If Oxford is already in Phase 2 in Bangladesh with 300 people, why is Tokyo still in Phase 1?
Different vaccines, different timelines. Oxford may have had earlier animal data or different regulatory pathways. Phase 1 is about safety; Phase 2 tests whether it actually works. You can't skip Phase 1 just because someone else is ahead. Each candidate has to prove itself.
What happens if both vaccines work?
Then you have options. Different vaccines work better for different populations, different age groups, different storage conditions. Having two candidates means the world isn't dependent on a single supply chain. It also means faster deployment if outbreaks happen.